This page contains brief information about pegfilgrastim and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Pegfilgrastim is approved to treat:
- Neutropenia caused by myelosuppressive chemotherapy. It is used to reduce the chance of infection in patients with certain types of cancer.
Pegfilgastrim is a form of filgrastim that has polyethylene glycol (PEG) attached to it. This form stays in the body longer than does filgrastim, so it doesn’t need to be given as often. For more information, see the Drug Information Summary for Filgrastim.
More About Pegfilgrastim
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Pegfilgrastim - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Pegfilgrastim - Check for trials from NCI's list of cancer clinical trials now accepting patients.